Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated July 7, 2021, details the results of the 2021 Annual Meeting of Stockholders held on that date. Protalix Biotherapeutics, Inc. is a Delaware corporation with its principal executive offices in Hackensack, NJ.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Election of Directors: All seven nominees recommended by the Board were elected. Vote counts ranged from approximately 11.9 million to 17.4 million votes "For" per director, with significant broker non-votes (8,191,694) recorded for each.
- Executive Compensation: Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers. The vote was 12,773,963 "For," 5,739,748 "Against," and 75,474 "Abstain."
- Ratification of Auditors: Stockholders ratified the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), as the independent registered public accounting firm for the fiscal year ending December 31, 2021. The vote was 26,185,693 "For," 425,671 "Against," and 169,515 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the final composition of the Board of Directors following the election of the seven nominees.
- Note the significant number of broker non-votes (over 8 million) regarding the election of directors, which may indicate a large portion of shares held in street name where brokers lacked discretionary voting power.
- Confirm the appointment of Kesselman & Kesselman as the independent auditor for the 2021 fiscal year.
- Review the "Against" vote count for executive compensation (5.7 million) to gauge shareholder sentiment on pay practices.